“Patients with Gilles de la Tourette syndrome (GTS) experience reduced function and impaired quality of life. The current medical treatments for this syndrome can cause significant side effects and offer partial symptomatic relief.

In a few small trials medical cannabis (MC) has been suggested to offer symptomatic relief with a relatively benign side effect profile.

We conducted a real-life assessment of clinical benefit and adverse effects of chronic MC treatment among patients with GTS.

CONCLUSION:

MC seems to hold promise in the treatment of GTS as it demonstrated high subjective satisfaction by most patients however not without side effects and should be further investigated as a treatment option for this syndrome.”

https://www.ncbi.nlm.nih.gov/pubmed/30292733

https://www.prd-journal.com/article/S1353-8020(18)30429-2/fulltext